Drug Profile

Research programme: antithrombotics - Tobira Therapeutics

Alternative Names: RB-571/RB-515; REG3

Latest Information Update: 23 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Archemix Corporation; Regado Biosciences
Developer Tobira Therapeutics
Class Antithrombins; Nucleotide aptamers; Oligonucleotides
Mechanism of Action Glycoprotein inhibitors; Platelet membrane glycoprotein VI inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cardiovascular disorders; Diabetic angiopathies

Most Recent Events

23 Feb 2023 Discontinued - Preclinical for Cardiovascular disorders in USA (IV)
23 Feb 2023 Discontinued - Preclinical for Diabetic angiopathies in USA (IV)
28 Jul 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com